Key Takeaways Boston Scientific expanded in oncology and hypertension with Intera Oncology and SoniVie deals. Acquisitions boosted BSX Q2 revenues by 450 basis points, strengthening therapeutic portfolios. BSX's WATCHMAN franchise grew 28% in Q2, aided by CE Mark for next-gen FLX Pro device. Boston Scientific (BSX) is poised for growth in the upcoming quarters, driven by its impressive strategic acquisitions. The long-term prospects of the WATCHMAN devices are encouraging. Meanwhile, headwinds like currency ...